

Andrew R Branagan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4248212/publications.pdf>

Version: 2024-02-01

76
papers

3,831
citations

201385

27
h-index

128067

60
g-index

80
all docs

80
docs citations

80
times ranked

2821
citing authors

#	ARTICLE	IF	CITATIONS
1	Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. <i>Haematologica</i> , 2022, 107, 1163-1171.	1.7	11
2	Long-term follow-up of ibrutinib monotherapy in treatment-naïve patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2022, 36, 532-539.	3.3	50
3	Venetoclax in Previously Treated Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 63-71.	0.8	53
4	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. <i>Lancet Haematology</i> , 2022, 9, e143-e161.	2.2	44
5	Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy. <i>Blood Advances</i> , 2022, 6, 1015-1024.	2.5	12
6	Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. <i>Cancer</i> , 2022, 128, 1996-2004.	2.0	12
7	SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 547-556.	0.2	6
8	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. <i>Blood Advances</i> , 2022, 6, 3332-3338.	2.5	4
9	Zanubrutinib for the treatment of adults with Waldenström macroglobulinemia. <i>Expert Review of Anticancer Therapy</i> , 2022, , .	1.1	3
10	Abstract CT550: Phase II study of acalabrutinib and an anti-CD20 monoclonal antibody in patients with anti-MAG mediated neuropathy. <i>Cancer Research</i> , 2022, 82, CT550-CT550.	0.4	0
11	A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 8012-8012.	0.8	2
12	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 565-575.	0.8	98
13	Role of MBD3-SOX2 axis in residual myeloma following pomalidomide. <i>Leukemia</i> , 2021, 35, 3319-3323.	3.3	4
14	Clinical application of genomics in Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1805-1815.	0.6	3
15	Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias. <i>Blood Advances</i> , 2021, 5, 1535-1539.	2.5	17
16	Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 194, 730-733.	1.2	16
17	Cell-free DNA analysis for detection of MYD88 ^{L265P} and CXCR4 ^{S338X} mutations in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, E250-E253.	2.0	8
18	Perceptions of prognosis in caregivers of multiple myeloma (MM) patients. <i>Journal of Clinical Oncology</i> , 2021, 39, 12082-12082.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. <i>Blood</i> , 2021, 138, 1535-1539.	0.6	32
20	Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia. <i>HemaSphere</i> , 2021, 5, e624.	1.2	15
21	Lifestyle considerations in multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 172.	2.8	11
22	Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 4082-4082.	0.6	0
23	COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia. <i>Blood</i> , 2021, 138, 3801-3801.	0.6	1
24	Pirtobrutinib (LOXO-305) Is Active and Overcomes ERK Related Pro-Survival Signaling in Ibrutinib Resistant, BTK Cys481 Mutant Expressing WM and ABC DLBCL Lymphoma Cells Driven By Activating MYD88 Mutations. <i>Blood</i> , 2021, 138, 2261-2261.	0.6	6
25	Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 3839-3839.	0.6	3
26	Real-World Observations and Practical Considerations of Subcutaneous Daratumumab Administration in Multiple Myeloma. <i>Blood</i> , 2021, 138, 5018-5018.	0.6	2
27	Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 3044-3044.	0.6	1
28	Molecular Features and Clinical Outcomes of Extramedullary Plasmacytomas. <i>Blood</i> , 2021, 138, 398-398.	0.6	1
29	Preliminary Clinical Response Data from a Phase 1b Study of Mavoxifafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations. <i>Blood</i> , 2021, 138, 1362-1362.	0.6	8
30	A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma. <i>Blood</i> , 2021, 138, 5043-5043.	0.6	0
31	Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. <i>HemaSphere</i> , 2020, 4, e433.	1.2	11
32	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , 2020, 7, e827-e837.	2.2	96
33	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. <i>Journal of Clinical Oncology</i> , 2020, 38, 1198-1208.	0.8	103
34	Current Treatment Strategies for Multiple Myeloma. <i>JCO Oncology Practice</i> , 2020, 16, 5-14.	1.4	28
35	A phase II, single-arm study of denosumab in multiple myeloma patients with renal insufficiency. <i>Journal of Clinical Oncology</i> , 2020, 38, 8520-8520.	0.8	0
36	Extending Dosing Intervals of Denosumab As a Maintenance Strategy in Multiple Myeloma: A Real-World Experience at a Large Academic Cancer Center. <i>Blood</i> , 2020, 136, 13-13.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Updates and rationale of clinical trials in multiple myeloma. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e59.	0.6	0
38	Genomic landscape of Waldenström's macroglobulinemia. <i>HemaSphere</i> , 2019, 3, 58-61.	1.2	1
39	Current management and emerging treatment strategies for multiple myeloma. <i>Rinsho Ketsueki/the Japanese Journal of Clinical Hematology</i> , 2019, 60, 1243-1256.	0.5	7
40	A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 3169-3169.	0.6	6
41	Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 296-304.e2.	0.2	39
42	2168. <i>Journal of Clinical and Translational Science</i> , 2017, 1, 31-32.	0.3	0
43	Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice. <i>Nature Medicine</i> , 2016, 22, 1351-1357.	15.2	132
44	Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. <i>New England Journal of Medicine</i> , 2016, 374, 555-561.	13.9	167
45	Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial. <i>Blood</i> , 2016, 128, 2139-2139.	0.6	1
46	Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice. <i>Blood</i> , 2015, 126, 120-120.	0.6	1
47	Fluzone® High-Dose Influenza Vaccine with a Booster Is Associated with Low Rates of Influenza Infection in Patients with Plasma Cell Disorders. <i>Blood</i> , 2015, 126, 3058-3058.	0.6	1
48	Lenalidomide and Rituximab in Waldenström's Macroglobulinemia. <i>Clinical Cancer Research</i> , 2009, 15, 355-360.	3.2	124
49	Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. <i>Blood</i> , 2009, 113, 3673-3678.	0.6	141
50	CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemia. <i>Blood</i> , 2008, 112, 4683-4689.	0.6	74
51	Thalidomide and rituximab in Waldenström macroglobulinemia. <i>Blood</i> , 2008, 112, 4452-4457.	0.6	135
52	Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenström's Macroglobulinemia: Results of WMCTG Trial 03-248. <i>Clinical Cancer Research</i> , 2007, 13, 3320-3325.	3.2	186
53	Genetic Linkage of Fcγ ₁ RIIIa and Fcγ ₃ RIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 286-290.	1.4	30
54	Novel Agents in the Treatment of Waldenström's Macroglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, S199-S206.	1.4	15

#	ARTICLE	IF	CITATIONS
55	Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. American Journal of Hematology, 2007, 82, 83-84.	2.0	64
56	Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Experimental Hematology, 2007, 35, 1366-1375.	0.2	61
57	CD52 Is Expressed on Human Mast Cells and Is a Potential Therapeutic Target in Waldenström's Macroglobulinemia and Mast Cell Disorders. Clinical Lymphoma and Myeloma, 2006, 6, 478-483.	1.4	41
58	Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström's Macroglobulinemia. Journal of Clinical Oncology, 2005, 23, 474-481.	0.8	263
59	CD5, CD10, and CD23 Expression in Waldenström's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2005, 5, 246-249.	2.1	71
60	CHOP plus Rituximab Therapy in Waldenström's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2005, 5, 273-277.	2.1	55
61	Abnormal Expression of the Plasma Cell Differentiation Factor X-Box Protein 1 (Xbp-1) in Waldenström's Macroglobulinemia.. Blood, 2005, 106, 1003-1003.	0.6	2
62	Phase II Study of CC-5013 (Revlimid) and Rituximab in Waldenström's Macroglobulinemia: Preliminary Safety and Efficacy Results.. Blood, 2005, 106, 2443-2443.	0.6	7
63	A Novel Functional Role for Soluble CD27 in the Pathogenesis of Waldenström's Macroglobulinemia.. Blood, 2005, 106, 4701-4701.	0.6	6
64	Establishment of a Waldenström's Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice.. Blood, 2005, 106, 979-979.	0.6	5
65	Bone Marrow Mast Cells Are Significantly Increased in Patients with Waldenström's Macroglobulinemia, and Their Number Following Therapeutic Intervention Is Dependent on Extent of Response.. Blood, 2005, 106, 980-980.	0.6	3
66	Clinical Responses to Sildenafil in Waldenström's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2004, 5, 205-207.	2.1	26
67	B-Lymphocyte Stimulator Protein (BLYS) Is Expressed by Bone Marrow Mast and Lymphoplasmacytic Cells in Waldenström's Macroglobulinemia, and Provides Signaling for Growth, Survival and IgM Secretion.. Blood, 2004, 104, 3358-3358.	0.6	13
68	High Levels of Soluble Immunoregulatory Receptors in Patients with Waldenström's Macroglobulinemia.. Blood, 2004, 104, 4881-4881.	0.6	4
69	Vascular Endothelial Growth Factor (VEGF) Is a Growth and Survival Factor in Waldenström's Macroglobulinemia.. Blood, 2004, 104, 4892-4892.	0.6	2
70	IgA and IgG Hypogammaglobulinemia Persists in Most Patients with Waldenström's Macroglobulinemia Despite Therapeutic Responses, Including Complete Remissions.. Blood, 2004, 104, 4896-4896.	0.6	5
71	Campath-1H in Waldenström's Macroglobulinemia.. Blood, 2004, 104, 4924-4924.	0.6	4
72	Lymphoplasmacytic Cells and Mast Cells Are Targets for Imatinib Mesylate (Gleevec, Glivec) in Waldenström's Macroglobulinemia.. Blood, 2004, 104, 4929-4929.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 127-131.	0.8	86
74	Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 116-120.	0.8	304
75	Treatment recommendations in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 121-126.	0.8	94
76	Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 2003, 30, 110-115.	0.8	841